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Abstract
Most health care recommendations in the United States have 
come from trials designed to measure efficacy of medical 
interventions, with randomized controlled trials considered 
the gold standard for evidence-based medicine. Comparative 
effectiveness research has become an essential component of 
research to help define the benefits, risks, and effectiveness of 
different interventions for a particular illness. Comparative 
effectiveness research is informally defined as an assessment of all 
available options for a specific medical condition, with intent to 
estimate effectiveness in specific subpopulations. In this article, 
we contrast efficacy-based healthcare research and recommen-
dations in the United States, under the model of evidence-
based medicine, to the contemporary paradigm of comparative 
effectiveness research. We review the recent emphasis by the 
federal government on comparative effectiveness research. 
Finally, we review the limitations of effectiveness and efficiency.
(I)  What are the limitations behind current medical recommen-
dations in the United States?
Currently, most healthcare recommendations in the United 
States are based on studies designed to evaluate efficacy, which 
measures whether one novel intervention could have an impact 
on outcomes under ideal conditions.1 The gold standard of 
proving efficacy is a randomized controlled trial (RCT). Trials 
of efficacy have been crucial in the discovery of diagnostic tests, 
medications, surgical instruments, and systems of medical 
delivery.
However, medical recommendations based solely on efficacy are 
limited for a number of reasons.1-3 The results of an efficacy trial 
are aimed to provide a therapy for a homogenous population of 
healthy participants under highly-controlled conditions, which 
may not reflect the population heterogeneity seen in community 
practice. Due to the long study periods of efficacy trials, published 
results may be lagging behind the latest scientific research and 
interventions, making trial results when an immediate medical 
decision is necessary. As level I evidence from RCTs does not 
always exist, recommendations are based rather on various 
reviews of differing objectives, outcome measures, and study 
qualities. In addition, testing for efficacy examines all potential 
interventions that may have incremental benefits when no 
proven therapy exists, thereby not aiding in practical medical 
decision making between already accepted treatment options. 
RCTs are usually limited to major academic institutions, which 
have established databases and scientists devoted to publication 
of the data. RCTs typically exclude smaller institutions and 
private practices, which may serve patient subpopulations. These 
patient subpopulations may not present to the large academic 
institutions and may respond differently to a recommended 
therapy. The potential benefits at the clinical trial level do not 
always translate to real-world improvements as well, when 
other factors such as time and cost are factored in. Furthermore, 
efficacy-based trials simply may not accrue enough patients to 
answer a queried hypothesis. Finally, trials of efficacy are typically 
expensive, precluding testing of other potential interventions 
that may have incremental benefits. These limitations call for 
complementary research that is designed to better inform the 
clinical decision making process.
(II)  What is comparative effective research?
Comparative effectiveness research (CER) is separate from and 
complementary to research approaches that measure efficacy. 
CER is informally defined as an assessment of available options 
for treating specific medical conditions in selected groups 
of patients.4,5 CER focuses on treatment effectiveness, i.e. 
whether the intervention makes an impact under “real-world” 
conditions, and efficiency, i.e. whether an intervention is worth 
the resources it consumes.1 The contemporary concept of CER 
is to incorporate all available data to direct practitioners to 
optimal patient-specific treatment decisions. Studies in CER 
are recommended to: (1) influence clinical decision making by 
identifying the most effective health care options where clear 
options exist, (2) support the development of personalized 
or stratified medicine by examining the racial, ethnic, 
socioeconomic, and geographic variations in care that affect 
health outcomes, (3) find the clinical characteristics that predict 
which intervention would be most successful in an individual 
patients, (4) integrate outcome measures, including patient-
reported quality of life and costs to patients and providers, and 
(5) link data from public and private entities.2,5-9 Examples of 
CER studies are now present throughout medicine and include 
research designed to evaluate the effectiveness of medical 
interventions in cardiology, endocrinology, medical oncology, 
radiation oncology, and psychiatry.10-15
CER also focuses on targeting specific patient subpopulations 
through predictive biomarkers and companion diagnostics.16,17 
Predictive biomarkers are baseline characteristics that categorize 
patients by their likelihood of responding to a particular 
treatment, including favorable and unfavorable responses. 
Examples of predictive biomarkers include Apolipoprotein E4 
(APOE4) status in Alzheimer’s patients and Human Epidermal 
growth factor Receptor 2 (HER2) overexpression in breast cancer 
patients.18,19 Companion diagnostics are predictive biomarkers 
that are developed into commercially available diagnostic tests, 
such as Oncotype DX for breast cancer.17
Biomarker-specific therapeutic interventions are combined with 
companion diagnostics to target a patient subpopulation for 
treatment. The combination of one therapy with one biomarker 
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is the sine qua non of ‘personalized’ stratified medicine. By 
targeting patients on the basis of biomarkers, patient subpop-
ulations that respond differently to treatment are identified, 
thereby generating more favorable benefit–risk profiles for 
the therapeutic. This is in contrast to the traditional empirical 
‘all-comers’ approach of efficacy-based trials, where any patients 
with the disease of interest may be enrolled.20 Estimates of 
treatment effect size that are limited to biomarker-expressing 
patient subpopulations may better reflect the impact of a 
candidate therapeutic agent. Moreover, trials limited to patient 
subpopulations avoid exposure of others to a drug since these 
individuals would lack the predictive biomarker. CER may 
therefore strengthen the ability to measure effect and improve 
patient safety.
(III)  Quantifying the success of comparative effectiveness 
research
The expected net present value (eNPV) has been used to estimate 
the potential success of medical studies including comparative 
effectiveness trials.20,21 The eNPV is the risk-adjusted sum of the 
value of an investment or project. It integrates the costs necessary 
to undertake a potential project (e.g. cost to develop a clinical 
test, timing of development and approval, time to physician 
adoption) to the potential monetary benefits (e.g. the sales and 
lifetime gross profit of a test).21 Companies tend to fund projects 
that have a positive eNPV because it indicates a value-adding 
investment.20,22 With substantial prior confidence in predictive 
biomarkers, a stratified medicine development strategy often 
generates a higher eNPV than an ‘all-comers’ approach.
The eNPV has been used to estimate the potential success of 
medical studies.20 For example, in oncology, eNPV modeling 
studies for HER2, the biomarker used for response to the drug 
trastuzumab, mirrored the actual benefits of trastuzumab in 
clinical trials that included patients expressing HER2.16,23, 24 In 
neurology, eNPV modeling studies have shown that prospective 
stratified medicine approaches that identify patients positive for 
APOE4, the candidate biomarker for bapineuzumab, created a 
six-time greater eNPV value than the traditional approach of 
using bapineuzumab on all Alzheimer’s patients.16 In these eNPV 
modeling studies, patient subpopulations that would respond 
best to a therapy were identified. The eNPV of conducting trials 
for therapies aimed directly at the subpopulations mirrored the 
actual successes of the trials.
(IV)  The impetus behind comparative effectiveness research in 
the United States
CER is not a novel idea, but the United States government has 
recently provided a new push for CE.25 In recognition of the 
value in CER research, the American Recovery and Reinvestment 
Act of 2009 allocated $1.1 billion to toward CER and the 
Patient Protection and Affordable Care Act of 2010 created the 
Patient Centered Outcomes Research Institute (PCORI) with 
an estimated $600 million yearly funding to pursue CER.26 
Both PCORI and the Agency for Healthcare Research and 
Quality (AHRQ) define CER as research “designed to inform 
health-care decisions by providing evidence on the effectiveness, 
benefits, and harms of different treatment options. The evidence 
is generated from research studies that compare drugs, medical 
devices, tests, surgeries, or ways to deliver health care.”27
Controversy persists on whether costs of care should be included 
as a component of CER. Based on the guidelines of PCORI and 
the Centers for Medicare and Medicaid Services, cost will not 
be considered in reimbursement or in investigations of CER, 
and cost per quality adjusted life years analyses are specifically 
prohibited. However, in the current budget climate and limited 
medical resources, cost has become an important consideration, 
if not officially sanctioned. Unofficially, CER studies include 
analyses of the economic impact of potential interventions with 
cost-effective and cost-benefit analyses.28,29
(V) CER follows studies that establish efficacy
CER will be crucial for the treatment of patients with known 
biomarkers and multiple modalities of therapy available. 
Nonetheless, dynamic interactions exist among the prevalence 
of predictive biomarkers, the clinical performance of the 
companion diagnostic, and the effect of a therapy.16 First, 
if a therapy has a rapid efficacy onset and acceptable safety 
profile, the predictive biomarkers may not be necessary since 
a physician may rapidly determine therapeutic response.20 
Second, if the companion diagnostic is not widely distributed, 
then it will be impossible to screen for a biomarker. Third, the 
need to screen more patients with a companion diagnostic may 
lengthen the duration of a study. Prospective RCTs will still be 
necessary to validate the companion diagnostic and establish the 
predictive value, which would increase the cost of development 
and negate potential savings. Fourth, treatment response of 
a biomarker-specific therapy may not correlate strongly with 
biomarker expression, as was the case with EGFR expression and 
cetuximab, where the expression of EGFR did not correlate with 
the expected benefit in progression-free or overall survival.30 If 
a companion diagnostic does not already exist for a disorder, its 
development adds to the risk of failure and a negative eNPV. 
Further, information regarding the prevalence of a biomarker 
may not be available in a large database of patients, precluding 
the use of that therapy. Finally, biomarker-specific therapies 
face restricted pricing flexibility for their use in a smaller patient 
population.16 If there are fewer people who could benefit from 
the drug, the company providing the drug must tailor the price 
for these individuals. Thus, studies of effectiveness or efficiency 
are not always feasible, while studies of efficacy continue to be 
important in innovation and population medicine.
Conclusion
Current health care recommendations in the United States 
have mostly come from trials of efficacy, which ask if a therapy 
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could work in an ideal situation. In contrast, CER focuses on 
whether an intervention makes an impact under “real-world” 
conditions (its effectiveness) and if an intervention is worth the 
resources it consumes (its efficiency). CER integrates the use 
of predictive biomarkers and companion diagnostics to predict 
which intervention would be most successful in an individual 
patient. The eNPV of such studies is higher than that of efficacy-
based RCTs, and the US government has recently provided a 
financial impetus for increasing CER. Nonetheless, CER has 
elicited concerns for a variety of reasons, including method-
ological challenges, choice of appropriate comparator, lack of 
biomarker data in large databases, and lack of existing efficacy 
trials. The push toward CER represents an extension of research 
resources beyond the traditional biomedical research model of 
evidence-based medicine, in which carefully-designed RCTs to 
measure efficacy reign supreme. Future health care recommen-
dations will come from studies of effectiveness and efficiency.
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